Bachem Holding AG (0QND.L) LSE
Currency In CHF
- General
- Statistics
- Historical Data
- Profile
- Financials
Bachem Holding AG
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
2207
First IPO Date
December 03, 2015
Key Executives
| Name | Title | Pay | Year Born |
| Anne-Kathrin Stoller | Chief Executive Officer | 0 | 1974 |
| Daniel Grotzky | Head of Group Communications | 0 | N/A |
| Gunther Loidl | Chief Technology Officer | 0 | 1970 |
| Achim Pluckebaum | Chief Information Officer | 0 | N/A |
| Alain Schaffter | Chief Financial Officer | 0 | 1977 |
| Hans van Hees | Chief Operations Officer | 0 | 1969 |
| Michael Suter | Vice President of Global Accounting | 0 | N/A |
| Barbora Blaha | Head of Investor Relations | 0 | N/A |
| Torsten Wohr | Chief Commercial Officer | 0 | 1968 |
| Viviane Minden | Chief Human Resources Officer | 0 | N/A |
Description
Bachem Holding AG provides essential products to pharmaceutical and biotechnology companies worldwide, supporting their activities from early research and clinical trials through to commercial manufacturing. The company's primary focus is on the development, production, and regulatory assistance for peptide active pharmaceutical ingredients (APIs), particularly novel peptide and oligonucleotide compounds. Additionally, Bachem offers commercial-grade new chemical entities (NCEs) and generic APIs, complemented by services including project management, quality assurance, regulatory guidance, analytical testing, Good Manufacturing Practice (GMP) compliant production, research-grade material manufacturing, and integrated supply chain solutions. Established in 1971, this Swiss company is headquartered in Bubendorf and operates as a subsidiary of Ingro Finanz AG.
